Drug Profile
Research programme: mRNA cancer vaccines - BioNTech/Genentech
Latest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator BioNTech
- Class Cancer vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer